Clinical Trials Browser

Terminated × Has results × talazoparib × Clear all

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Phase 1/2 Terminated

223 enrolled 50 charts

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04598321 2023-10-12

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Phase 1 Terminated

1 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2 Terminated

202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Phase 3 Terminated

79 enrolled 18 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03637491 2022-01-26

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Phase 1/2 Terminated

36 enrolled 22 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03499353 2021-11-09

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2 Terminated

61 enrolled 63 charts

Breast Neoplasms

NCT04052204 2021-10-14

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT02326844 2020-08-18

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Phase 2 Terminated

3 enrolled 10 charts

Ovarian Neoplasms

NCT02034916 2019-10-14

ABRAZO

Phase 2 Terminated

84 enrolled 21 charts

Breast Neoplasms